Dr. Lawrence E. Samelson is the chief of the Laboratory of Cellular and Molecular Biology and the deputy director of the Center for Cancer Research at the National Cancer Institute, NIH.
Dr. Samelson was part of the team that first characterized the full T cell receptor (TCR) complex and discovered the TCR’s zeta chain, and was involved in the development of the first anti-CD3 murine monoclonal antibody. His current work focuses on characterizing the signaling pathways linked to the TCR complex and how they contribute to effective immune responses. He has been elected to the American Association for the Advancement of Science, and in addition to being a member of CRI’s Scientific Advisory Council, Dr. Samelson serves on the Postdoctoral Fellowship Review Committee.
Understanding and manipulating the signaling pathways [of T cells] is how immunotherapy will continue to improve.
Let's spread the word about Immunotherapy! Click to share this page with your community.